12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Oral solithromycin: Phase II data

Top-line data from an open-label Phase II trial in 22 evaluable patients with uncomplicated urogenital gonorrhea infection showed that a single oral dose of solithromycin met the primary endpoint by achieving a 95% successful bacterial eradication rate as measured by conversion from positive baseline urethral or cervical cultures to negative at day 7. Specifically, 100% of patients achieved successful bacterial...

Read the full 276 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >